Truist Securities Maintains Buy on Abivax, Raises Price Target to $155
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ: ABVX ) with a Buy and raises the price target from $135 to $155.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.